First-line pertuzumab-trastuzumab-docetaxel for HER2-positive locally recurrent or metastatic breast cancer in Chinese patients

The phase 3 PUFFIN trial at 15 centers in China evaluated addition of pertuzumab to trastuzumab plus docetaxel for previously untreated HER2-positive locally recurrent or metastatic breast cancer. Addition of pertuzumab was associated with improvement of progression-free survival as well as overall survival. Safety was similar in both arms, with 73.8% (pertuzumab arm) and 69.2% (placebo arm) of patients experiencing grade 3 or higher adverse events. The authors conclude that results of PUFFIN were consistent with results of CLEOPATRA in non-Chinese patients.